Lightcalls.com
 

Background The Canada Customs and i...

Background

The Canada Customs and income Agnecy (CCRA) is continuing to increase its attention forward the transactions between taxpayers and related non-residents to make secure Canadian taxpayers do not abate their Canadian tax liability by the and of non-arms'-length pricing-in other words: inappropriate transfer pricing.

Since the introduction of Canada's general transfer pricing legislation (contained in Section 247 of the Income Tax Act), the CCRA's International Tax Directorate (ITD), which is responsible for the CCRA's international audit program and providing technical assistance to the local tax offices, has more than doubled in size. Staffing of international tax auditors at local offices has also increased; in fact, for the 2002/2003 year, another 17% increase was budgeted

Today, taxpayers face considerable challenges in defending their transfer pricing during a CCRA audit. The CCRA now assigns trained and specialized international examiners to focus solely upon the taxpayer's transfer pricing and other international transactions. The international examiners are supported by dint of economists and other experts and specialists occupyed by the ITD, and are motivated to find adjustments, especially in light of the lusty recommendation that the CCRA "need to be more effective in carrying disclosed audits of international issues," offer forth in the Auditor General of Canada's December 2002 Report.



This is significantly different from the way things used to be when, typically, united examiner would be assigned to audit the two a taxpayer's domestic and international issues, and therefore might lack the expertise and the time to closely scrutinize transfer pricing.

The risk of a taxpayer's transfer pricing coming in subordination to close scrutiny has never been greater. More taxpayers are now being enslaveed to transfer pricing audits, and more transfer pricing reassessments are being issued.

Transfer pricing audits

All cross-border, related-party transactions will be closely scrutinized, including management services, result sales, transactions involving intangibles, and guarantees. In addition, the CCRA has indicated it will closely examine any restructuring that, in its opinion, has produc a non-arm's duration result (i.e. the CCRA may argue that the shut up down of a Canadian manufacturing line has benefited a related-party manufacturer).

Generally, the CCRA will aggressively challenge the following items:

* Royalty amounts;

* Intra-group richnesss that have been allocated among related entities based solely forward revenues;

* Inbound management services priced at a outlay plus mark-up or on a royalty basis;

* Outbound management services that have been priced at splendor with no mark-up or not charged at all.

* Pricing for performance sales to related parties that differ from the pricing charged to unrelated parties, plane when volumes may differ significantly.

Without comprehensive documentation prepared concurrently in accordance with an accepted methodology, there's a greater likelihood of the CCRA examiner concluding that the pricing was too cheap for sales to a related non-resident, and too high for purchases. Further, without becoming documentation, the CCRA may use shrouded comparables and may ignore related-party transactions that bear a downward or offsetting adjustment (i.e. reduction of taxable income) for the taxpayer.

Within the global transfer pricing community, there are significant differences of opinion as to the specific approach, methodology, and application in determining arms-length pricing. The CCRA's transfer pricing guidelines, as wager out in IC 87-2R International Transfer Pricing, set forth only one point of view-taxpayers should not simply accept proposals and arguments bring forward forth by the CCRA based in succession IC 87-2R.

Conversely, there may be occasions when a CCRA examiner does not completely or technically adhere to IC 87-2R; in these circumstances, it is appropriate to use the tables on the CCRA and apply IC 87-2R to dispel its arguments.

Resolution

Transfer pricing is not an exact science. If the taxpayer does not have full and thorough documentation supporting their pricing, the CCRA audit will generally issue in the issuance of a reassessment. When it get tos to fighting transfer pricing reassessments, many taxpayers file a protective objection and inquire for relief through "Competent Authority."

Under suitable Authority, the CCRA and the particular foreign tax authority will review the transfer pricing adjustment, negotiate with each other, and suggest a resolution that eliminates double taxation (i.e. allow the related party to obtain a corresponding deduction, direct the local CCRA office to vacate the reassessment, or combination thereof). Unfortunately, the qualified Authority process is both prolonged (anywhere from 6 to 24 months) and of great price (preparation of submissions); however, the proces is necessary, as neither the CCRA nor principally foreign tax authorities are receptive to the idea of taxpayers simply adjusting their tax responds for adjustments imposed by foreign tax authorities.



Other Articles
 -Morphotek will collaborat...
 -Eksigent Technologies nam...
 -The benefits of outsourci...
 -Sartorius Corporation ...
 -In our previous column, w...
 -Efoora appointed Michael ...
 -Affymax appointed Anne-Ma...
 -Traditionally, continuous...
 -New Brunswick Scientific ...
 -The German-American firm ...
 -Don G. Burstyn, formerly ...
 -American patients are mor...
 -Summary Prior to va...
 -BioPharm Editorial Adviso...
 -Australia agreed to spend...
 -The Biotechnology Industr...
 -Ambion, The RNA Company i...
 -Therapies based on living...
 -A recent survey found tha...
 -ViroLogic will acquire Ac...
 -Cardinal Health named Joh...
 -One of the greatest chall...
 -As the president of a sma...
 -Sweden-based Biovitrum wi...
 -Nanogen appointed David L...
 -The Experion Process Know...
 -Although biomedical resea...
 -The Supreme Court of Cana...
 -Netherlands-based DSM Bio...
 -David A. Smoller joined S...
 -A few months ago, I wrote...
 -Panacos Pharmaceuticals w...
 -Karen K. Vaccaro will res...
 -Acceleron Pharma appointe...
 -Two quarterly meetings of...
 -Illinois-based Abbot Labo...
 -FKI Logistics announced t...
 -The following corrections...
 -It its widest definition,...
 -UK-based Xcellsyz will li...
 -Andrew P. Aromando joined...
 -Invitrogen's comprehensiv...
 -Last month, we described ...
 -The Swiss life sciences c...
 -Protein Design Labs (PDL)...
 -Model It HNMR, the newest...
 -Tech transfer, like chang...
 -QLT and Atrix Laboratorie...
 -Dendreon announced Christ...
 -Baxter Pharmaceutical Sol...
 -The biopharmaceutical ind...
 -GlaxoSmithKline announced...
 -Montreal-based Caprion Ph...
 -Xenova Group recently ann...
 -Cole-Parmer's new 192-pag...
 -Over the last decade ther...
 -Benchmark your facility p...
 -As biotechnology organiza...
 -Frederick D. Sancillo, fo...
 -Insmed acquired a recombi...
 -Baxter Pharmaceutical Sol...
 -Model It HNMR, the newest...
 -DA's regulation 21 CFR Pa...
 -Robert P. Ryan joined Ath...
 -A new report from Busines...
 -Biotest offers a complete...
 -Swagelok offers a brochur...
 -Partnering is a global ph...
 -Human Genome Sciences CEO...
 -Shorten the process devel...
 -The licensure of biotechn...
 -Rodger Currie joined Amge...
 -The GEA Filtration Model ...
 -A multi-channel chemistry...
 -From June 6-9, San Franci...
 -Skanska USA Building Inc....
 -New Brunswick Scientific'...
 -AVI BioPharma appointed P...
 -Ambion, The RNA Company, ...
 -"If you want to be a...
 -Xcellerex appointed Susan...
 -Researchers identified th...
 -Cool Spring Business Park...
 -In October 2003, Shenzhen...
 -Laureate Pharma appointed...
 -After a 6-5 vote by Calif...
 -QSourcing, a service of Q...
 -The recent discovery of &...
 -Affymax added Douglas L. ...
 -USDA recently approved tw...
 -BioPharm International is...
 -Serologicals has released...
 -This document by Shenzhen...
 -Robert Bronstein joined A...
 -Gloucester Gains Fujisawa...
 -With more than 30 years o...
 -Pall's SUPRAdisc II depth...
 -In today's competitive ma...
 -Protein Design Labs repor...
 -Charles A. Rice will repl...
 -AstraZeneca's Faslodex (f...
.
© 2006 Lightcalls.com All rights reserved.